1. Home
  2. Live Updates
  3. Prnewswire akeso inc

Live Breaking News & Updates on Prnewswire akeso inc

Stay informed with the latest breaking news from Prnewswire akeso inc on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Prnewswire akeso inc and stay connected to the pulse of your community

Oral report | The positive interim analysis results from the Phase III clinical study of Akeso's Cadonilimab (PD-1/CTLA-4 BsAb) plus chemotherapy as first-line treatment for advanced gastric cancer presented at 2024 AACR

SAN DIEGO, April 8, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the positive interim analysis results from Phase III clinical study of Cadonilimab (PD-1/CTLA-4 BsAb) combined with XELOX

United-states , American , Akeso-inc , American-association-for-cancer-research , Prnewswire-akeso-inc , Cancer-research ,

Oral report | The positive interim analysis results from the Phase III clinical study of Akeso's Cadonilimab (PD-1/CTLA-4 BsAb) plus chemotherapy as first-line treatment for advanced gastric cancer presented at 2024 AACR


SAN DIEGO, April 9, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the positive interim analysis results from Phase III clinical study of Cadonilimab (PD-1/CTLA-4 BsAb) combined with XELOX (capecitabine plus oxaliplatin) as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (AK104-302/COMPASSION-15) were released presented in the form of oral presentation at...

United-states , American , Prnewswire-akeso-inc , American-association-for-cancer-research , Cancer-research ,

Akeso Announced The Lancet Oncology Publishes Promising Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)

Akeso Announced The Lancet Oncology Publishes Promising Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)
kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.

United-states , Lin-shen , Guangdong , China , Peking , Beijing , American , Jafu-ji , Radiology-review-committee , China-national-medical-products-administration , Prnewswire-akeso-inc , University-cancer-hospital

Akeso Announced NDA Acceptance of IL-12/lL-23 Monoclonal Antibody Ebdarokimab for Moderate-to-severe Plaque Psoriasis by China NMPA

HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Akeso Inc. , a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines...

Hong-kong , China , Prnewswire-akeso-inc , Akeso-inc , National-center , New-drug-application , Drug-evaluation , State-drug-administration , Summit-therapeutics , Main-board , Stock-exchange

Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC

Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , Australia , China , Hong-kong , Canada , Japan , Akeso-inc , Prnewswire-akeso-inc , Summit-therapeutics , Main-board , Stock-exchange

Akeso Inc. Published 2023 Interim Results Positive Profit Alert

/PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing...

Canada , China , Japan , Akeso-inc , Company-for-the-reporting-period , Prnewswire-akeso-inc , Reporting-period , Summit-therapeutics , Akeso , Nc- ,

Promising 2-year updated data from cadonilimab presented at 2023 ASCO highlighting promising efficacy in PD-L1-negative patients

/PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso") released two-year updated data from a Phase Ib/II clinical study of cadonilimab – a first-in-class PD-1/CTLA-4...

United-states , China , Chinese , American , Remarkable , Prnewswire-akeso-inc , American-society-of-clinical-oncology , Akeso-inc , Clinical-oncology , Akeso , Nc-

Akeso Reported 2022 Annual Results

Strong sales fully demonstrated Akeso's commercialization ability: Products sales totaled RMB1,104.4 million, increasing 422% .开坦尼® (cadonilimab) recorded...

China , Japan , United-states , Canada , Michelle-xia , Sino-biopharmaceutical , Prnewswire-akeso-inc , Akeso-inc , Summit-therapeutics , Sino-biopharmaceutical-limited , Hodgkin-lymphoma , Breakthrough-therapy-designation-status

Patient Enrollment Completed for Phase III Clinical Trial of Akeso's Cadonilimab in Treatment of Gastric Cancer

/PRNewswire/ -- Akeso, Inc. (9926.HK) announced that patient enrollment has been completed for its pivotal Phase III clinical trial for cadonilimab...

Peking , Beijing , China , Ji-jiafu , Prnewswire-akeso-inc , Akeso-inc , Professor-ji-jiafu , Peking-cancer-hospital , Akeso , Nc- ,

Akeso Received First Tranche of US$300 Million Upfront Payment from Summit! Summit Is Accelerating Clinical Development of Ivonescimab

/PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company"), a commercial-stage biopharmaceutical company focused on developing and commercializing...

Prnewswire-akeso-inc , Akeso-inc , Summit-therapeutics , License-agreement , Executive-director , Akeso , Nc- ,